CNS Pharmaceuticals (CNSP) Receivables (2021 - 2023)
CNS Pharmaceuticals' (CNSP) quarterly Receivables came in at $197605.0 in Q4 2023, down 49.91% YoY from $394484.0 in Q4 2022, and little changed on a QoQ basis from $197605.0 in Q3 2023.
CNS Pharmaceuticals (CNSP) Receivables (2021 - 2023) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 3 years of Receivables data on file, last reported at $197605.0 in Q4 2023.
- Quarterly Receivables fell 49.91% year-over-year to $197605.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $197605.0 (down 49.91% YoY) and the FY2023 annual result came in at $197605.0, down 49.91% from the prior year.
- Receivables was little changed at $197605.0 in Q4 2023, from $197605.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.3 million in Q4 2021 to a low of $197605.0 in Q2 2023.
- A 3-year average of $459847.4 and a median of $197605.0 in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables sank 69.93% — and 2023, when it sank 49.91%.
- Tracing CNSP's Receivables over 3 years: stood at $1.3 million in 2021, then slumped by 69.93% to $394484.0 in 2022, then slumped by 49.91% to $197605.0 in 2023.
- The last three Receivables figures came in at $197605.0 (Q4 2023), $197605.0 (Q3 2023), and $197605.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | CNS Pharmaceuticals | 2.68 Mn | -4.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 197,605.00 |
| Sep 30, 2023 | 197,605.00 |
| Jun 30, 2023 | 197,605.00 |
| Dec 31, 2022 | 394,484.00 |
| Dec 31, 2021 | 1.31 Mn |